Leading GLP-1s expected to reach $50B in 2025 sales

By the end of 2025, consensus analyst estimates peg the combined sales of the four leading GLP-1 therapies, two apiece from Novo Nordisk and Eli Lilly, at about $50 billion. The three of those four that were on the market in 2022 had combined sales under $10 billion, almost all of which came from one drug: Novo’s Ozempic.

Ozempic semaglutide, a GLP-1 agonist that Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) markets for Type II diabetes, is expected to maintain its lead position atop the drug class, with sales growing from $8.4 billion in 2022 to an estimate of nearly $19 billion in 2025...